Please note, this OEL/ADE monograph also applies to Didanosine acetate (CAS RN 130676-58-3). Didanosine is a dideoxynucleoside compound in which the 3'-hydroxy (3'-OH) group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages, which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of human immunodeficiency virus (HIV) replication, acting as a chain-terminator of viral deoxyribonucleic acid (DNA) by binding to reverse transcriptase. Didanosine is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. It is indicated for use in in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Didanosine, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.